Breakthrough Therapy Designation
An FDA programme for drugs showing substantial improvement over available therapy based on preliminary clinical evidence. Breakthrough designation provides intensive FDA guidance, senior management involvement, and the most efficient path to approval among the FDA's expedited programmes.
Technical Context
Breakthrough Therapy requires: (1) the drug treats a serious condition, AND (2) preliminary clinical evidence shows substantial improvement over existing therapy on a clinically significant endpoint. 'Substantial improvement' is a higher bar than Fast Track's 'may offer advantage.' The preliminary evidence is typically from Phase I/II data showing meaningfully better outcomes. Benefits include: all Fast Track features PLUS intensive FDA guidance on efficient drug development (optimised clinical trial design, consideration of innovative endpoints and adaptive designs), organisational commitment involving senior FDA managers and experienced review staff, and cross-disciplinary meetings to address regulatory challenges proactively. The FDA granted Breakthrough Therapy designation to numerous peptide drugs, reflecting the therapeutic significance of advances in metabolic, oncological, and rare disease peptide therapeutics.